中基因减弱了Aβ纤维组合和粉样斑块的形成
Junmin Peng1, Masihuz Zaman1, Shu Yang1
1St Jude Children's Research Hospital.
Research square
|June 17, 2024
概括
在阿尔茨海默病模型中,Midkine (MDK) 蛋白降低了粉样蛋白-β (Aβ) 聚集和粉样蛋白斑块的形成. MDK淘汰会加剧粉样蛋白病理和微质激活,这表明MDK的保护作用.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 分子生物学分子生物学
背景情况:
- 在阿尔茨海默病 (AD) 大脑中的蛋白质组研究揭示了像中 (MDK) 这样的高调蛋白质.
- MDK在阿尔茨海默病发病过程中的作用,特别是从早期与粉样蛋白-β (Aβ) 的相关性,目前尚不清楚.
研究的目的:
- 调查midkine (MDK) 在粉样β (Aβ) 组合和聚合中的作用.
- 用5xFAD小鼠模型确定MDK对阿尔茨海默氏症病理学的影响.
主要方法:
- 在体外测试 (Thioflavin T,循环二重化,电子显微镜,NMR) 来评估MDK对Aβ40和Aβ42纤维素形成的影响.
- 在5xFAD小鼠模型中进行基因操纵 (Mdk淘汰),以研究体内效应.
- 在小鼠模型中,基于质谱的整体和聚合蛋白质的蛋白质特征分析.
主要成果:
- 发现MDK蛋白可以减轻Aβ40和Aβ42的纤维形成.
- 在5xFAD小鼠中,Mdk基因淘汰导致了粉样蛋白形成的增加和微质激活的增加.
- 蛋白质组分析显示,在Mdk淘汰赛模型中,Aβ,Aβ相关蛋白质和微质成分的大量积累.
结论:
- 中基因 (MDK) 通过减弱粉样蛋白-β (Aβ) 组合和粉样蛋白病理在阿尔茨海默病中起着保护作用.
- 在AD的背景下,MDK影响粉样蛋白形成并调节微质反应.
- 这些发现凸显了MDK作为对抗阿尔茨海默病进展的潜在治疗点.
更多相关视频
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
10.7K
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.2K
相关概念视频
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179